Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Vitamin D  COVID-19 treatment studies for Vitamin D  C19 studies: Vitamin D  Vitamin D   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
Vitamin D Endocrine System and COVID-19: Treatment with Calcifediol
Quesada-Gomez et al., Nutrients, doi:10.3390/nu14132716 (Review)
Quesada-Gomez et al., Vitamin D Endocrine System and COVID-19: Treatment with Calcifediol, Nutrients, doi:10.3390/nu14132716 (Review)
Jun 2022   Source   PDF  
  All Studies   Meta
Review of the use of calcifediol for COVID-19. Authors note several advantages of calcifediol vs. cholecalciferol: calcifediol induces a more rapid increase in circulating 250HD; calcifediol is more potent than cholecalciferol; calcifediol has a higher rate of intestinal absorption; and calcifediol has a linear dose-response curve, independent of initial serum levels.
Authors note that the available data strongly and consistently suggest that treatment with calcifediol can reduce the severity of COVID-19; and that calcifediol is cost-effective and widely available, without significant adverse effects. Authors propose to use calcifediol for the rapid correction of vitamin D deficiency in all patients in the early stages of COVID-19.
Quesada-Gomez et al., 29 Jun 2022, peer-reviewed, 7 authors.
Contact: (corresponding author),,,,,,
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin DAll
Abstract: nutrients Review Vitamin D Endocrine System and COVID-19: Treatment with Calcifediol Jose Manuel Quesada-Gomez 1,2, *, José Lopez-Miranda 1,3,4 , Marta Entrenas-Castillo 5 , Antonio Casado-Díaz 1,2,6 , Xavier Nogues y Solans 2,7 , José Luis Mansur 8 and Roger Bouillon 9, * 1 2 3 4 5 6 7 8 9 * Citation: Quesada-Gomez, J.M.; Lopez-Miranda, J.; Entrenas-Castillo, M.; Casado-Díaz, A.; Nogues y Solans, X.; Mansur, J.L.; Bouillon, R. Vitamin D Endocrine System and COVID-19: Treatment with Calcifediol. Nutrients 2022, 14, 2716. nu14132716 Academic Editor: Federica I. Wolf Received: 22 April 2022 Accepted: 27 June 2022 Published: 29 June 2022 Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Hospital Universitario Reina Sofía, 14004 Córdoba, Spain; (J.L.-M.); (A.C.-D.) Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES), Instituto de Salud Carlos III, 28029 Madrid, Spain; Departamento de Medicina Interna, Hospital Universitario Reina Sofía, 14004 Córdoba, Spain CIBER Fisiopatologia Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, 28029 Madrid, Spain Hospital QuirónSalud, 14004 Córdoba, Spain; Unidad de Gestión Clínica de Endocrinología y Nutrición, Hospital Universitario Reina Sofía, 14004 Córdoba, Spain Internal Medicine Department, IMIM (Hospital del Mar Medical Research Institute), Hospital del Mar, 08003 Barcelona, Spain Centro de Endocrinología y Osteoporosis La Plata, Buenos Aires B1902ADQ, Argentina; Clinical and Experimental Endocrinology, Department of Chronic Diseases and Metabolism, Catholic University of Leuven, 3000 Leuven, Belgium Correspondence: (J.M.Q.-G.); (R.B.) Abstract: The COVID-19 pandemic is the greatest challenge facing modern medicine and public health systems. The viral evolution of SARS-CoV-2, with the emergence of new variants with in-creased infectious potential, is a cause for concern. In addition, vaccination coverage remains in-sufficient worldwide. Therefore, there is a need to develop new therapeutic options, and/or to optimize the repositioning of drugs approved for other indications for COVID-19. This may include the use of calcifediol, the prohormone of the vitamin D endocrine system (VDES) as it may have potential useful effects for the treatment of COVID-19. We review the aspects associating COVID-19 with VDES and the potential use of calcifediol in COVID-19. VDES/VDR stimulation may enhance innate antiviral effector mechanisms, facilitating the induction of antimicrobial peptides/autophagy, with a critical modulatory role in the subsequent host reactive hyperinflammatory phase during COVID-19: By decreasing the cytokine/chemokine storm, regulating the renin–angiotensin–bradykinin system (RAAS), modulating neutrophil activity and maintaining the integrity of the pulmonary epithelial barrier, stimulating epithelial repair, and directly and indirectly decreasing the increased coagulability and prothrombotic tendency associated with severe COVID-19 and its..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop